基本數據
| CIK | 1819133 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Tango Therapeutics, Inc.
SEC Filings (Chronological Order)
本頁面提供了一個完整的、按時間順序排列的美國證券交易委員會（SEC）申報文件列表，不包括我們在其他地方提供的所有權申報。
| June 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 4, 2026 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 47-2452488 (State or other jurisdiction of incorporation) (Commission F |
|
| May 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): May 13, 2026 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q i113.ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39485 |
|
| May 13, 2026 |
Tango Therapeutics, Inc. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Tango Therapeutics, Inc. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Tango Therapeutics, Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its |
|
| May 13, 2026 |
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points BOSTON, May 13, 2026 (GLOBE NEWSWIRE) - Tango Therapeutics, Inc. |
|
| May 8, 2026 |
EX-10.1 Exhibit 10.1 April 13, 2026, revised on May 7, 2026 Daniella Beckman 87 Goden Street Belmont, MA 02478 Re: Separation Agreement Dear Daniella: This confirms our discussions relating to the end of your at-will employment with Tango Therapeutics, Inc. (“Tango” or the “Company”), which is a termination by the Company without Cause for purposes of the Employment Agreement between you and the C |
|
| May 8, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2026 TANGO THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39485 85-1195036 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 17, 2026 |
ACTIVE/206234477.2 2025UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39 |
|
| April 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 17, 2026 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2026 TANGO THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39485 85-1195036 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 15, 2026 |
EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Tango Therapeutics, Inc., a Delaware corporation (the “Company”), and Matthew Gall (the “Executive”), and is effective as of April 15, 2026 (the “Effective Date”). WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms and conditions c |
|
| April 15, 2026 |
EX-99.1 Exhibit 99.1 Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat - Matthew Gall appointed Chief Financial Officer - - Additional key appointments add expertise in clinical operations, corporate strategy and project leadership - BOSTON, April 15, 2026 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnol |
|
| March 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39485 TANGO THERAPEUT |
|
| March 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): March 5, 2026 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission F |
|
| March 5, 2026 |
As filed with the Securities and Exchange Commission on March 5, 2026 S-8 As filed with the Securities and Exchange Commission on March 5, 2026 Registration No. |
|
| March 5, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Tango Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity 2021 Stock Option and Incentive Plan Common Stock, $0.001 par value per share Other 6,797,023 $ 11.33 $ 77,0 |
|
| March 5, 2026 |
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment New clinical supply agreement with Erasca, plus ongoing Revolution Medicines collaboration, supports potential of vopimetostat as the preferred PRMT5 inhibitor for combination with RAS targeted therapies in oncology Cash position of $343 million as of December 31, 2025, with runway into 2028 beyond anticipated key data inflection points BOSTON, March 5, 2026 (GLOBE NEWSWIRE) - Tango Therapeutics, Inc. |
|
| January 8, 2026 |
The next wave of targeted therapies in oncology JP Morgan Healthcare Conference January 12, 2026 EX-99.2 Exhibit 99.2 The next wave of targeted therapies in oncology JP Morgan Healthcare Conference January 12, 2026 Disclaimer and safe harbor statement Certain statements in this presentation may be considered forward-looking statements. Forward-looking statements generally relate to future events, Tango’s future financial and operating performance, goals, expectations, beliefs, development pla |
|
| January 8, 2026 |
EX-10.3 Exhibit 10.3 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Tango Therapeutics, Inc., a Delaware corporation (the “Company”), and Malte Peters, M.D. (the “Executive”), and is effective as of the Effective Date, as defined in Section 23 herein. WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the ne |
|
| January 8, 2026 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT EX-10.1 Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (“Agreement”) is made between Tango Therapeutics, Inc., a Delaware corporation (the “Company”), and Barbara Weber, MD (the “Executive”) and is effective as of January 8, 2026 (the “Effective Date”). Except with respect to the Equity Documents (as defined below) and the Restrictive Covenant |
|
| January 8, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2026 TANGO THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39485 85-1195036 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| January 8, 2026 |
EX-10.2 Exhibit 10.2 LIMITED TERM EMPLOYMENT AGREEMENT between Tango Therapeuitcs, Inc. 201 Brookline Ave., Suite 901 Boston, MA 02215 represented by its authorized representative Julie Carretero – hereinafter referred to as the “Company” – and Malte Gerhard Peters – hereinafter referred to as the “Employee” – – hereinafter together “Parties“ and each individually “Party” – Art. 1 Employment / Are |
|
| January 8, 2026 |
EX-99.1 Exhibit 99.1 Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor - Founding CEO Barbara Weber, M.D. to become executive chair of the board of directors - - Malte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately – BOSTON, January 8, 2026 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (N |
|
| January 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 2, 2026 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commissio |
|
| January 5, 2026 |
Tango Therapeutics Appoints Sung Lee to Board of Directors EX-99.1 Exhibit 99.1 Tango Therapeutics Appoints Sung Lee to Board of Directors BOSTON, January 5, 2026 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Mr. Sung Lee to the Board of Directors. Mr. Lee has over 20 years of ex |
|
| December 8, 2025 |
CORRESP VIA EDGAR December 8, 2025 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| November 21, 2025 |
Calculation of Filing Fee Tables S-3 Tango Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward In |
|
| November 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 18, 2025 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commiss |
|
| November 21, 2025 |
TANGO THERAPEUTICS, INC. Dated as of [•], 202[•] Senior Debt Securities EX-4.5 Exhibit 4.5 TANGO THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’ |
|
| November 21, 2025 |
As filed with the Securities and Exchange Commission on November 21, 2025 S-3 As filed with the Securities and Exchange Commission on November 21, 2025 Registration No. |
|
| November 21, 2025 |
As filed with the Securities and Exchange Commission on November 21, 2025 S-3ASR Table of Contents As filed with the Securities and Exchange Commission on November 21, 2025 Registration No. |
|
| November 21, 2025 |
Calculation of Filing Fee Tables S-3 Tango Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward In |
|
| November 21, 2025 |
TANGO THERAPEUTICS, INC. Dated as of [•], 202[•] Subordinated Debt Securities EX-4.6 Exhibit 4.6 TANGO THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Subordinated Debt Securities TABLE OF CONTENTS(1) Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trust |
|
| November 21, 2025 |
TANGO THERAPEUTICS, INC. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENT EX-1.2 Exhibit 1.2 TANGO THERAPEUTICS, INC. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENT November 21, 2025 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 Ladies and Gentlemen: Tango Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: 1. |
|
| November 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): November 4, 2025 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commissio |
|
| November 4, 2025 |
Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights – Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7. |
|
| November 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q i113.ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39 |
|
| October 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2025 TANGO THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39485 85-1195036 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| October 24, 2025 |
TANGO THERAPEUTICS, INC. SECURITIES PURCHASE AGREEMENT EX-10.1 Exhibit 10.1 TANGO THERAPEUTICS, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (the “Agreement”) is made as of October 23, 2025 (the “Effective Date”), by and among Tango Therapeutics, Inc., a Delaware corporation (the “Company”), and the purchaser whose name and address is set forth on the signature pages hereof (the “Purchaser”) WHEREAS, the Purchaser desires to p |
|
| October 24, 2025 |
21,023,337 Shares of Common Stock Pre-Funded Warrants to Purchase 3,226,458 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. |
|
| October 24, 2025 |
EX-1.1 Exhibit 1.1 Execution Version TANGO THERAPEUTICS, INC. (a Delaware corporation) 21,023,337 Shares of Common Stock And Pre-Funded Warrants to Purchase 3,226,458 of Common Stock UNDERWRITING AGREEMENT October 23, 2025 Leerink Partners LLC as Representative of the several Underwriters c/o Leerink Partners LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 Ladies and Gentlemen: Tango T |
|
| October 24, 2025 |
TANGO THERAPEUTICS, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK EX-4.1 Exhibit 4.1 TANGO THERAPEUTICS, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: [ ], 2025 Tango Therapeutics, Inc. , a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered ass |
|
| October 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 23, 2025 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commissi |
|
| October 23, 2025 |
EX-99.1 Vopimetostat clinical update 23 October 2025 Exhibit 99.1 Disclaimer and safe harbor statement Certain statements in this presentation may be considered forward-looking statements. Forward-looking statements generally relate to future events, Tango’s future financial and operating performance, goals, expectations, beliefs, development plans, as well as development and clinical trial object |
|
| October 23, 2025 |
FWP Issuer Free Writing Prospectus dated October 23, 2025 Filed Pursuant to Rule 433 Registration No. |
|
| September 25, 2025 |
144 0001688327 XXXXXXXX LIVE 0001819133 Tango Therapeutics, Inc. 001-39485 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215 (857) 320-4900 Third Rock Ventures IV, L.P. 10% Stockholder Common BTIG, LLC 350 Bush Street 9th Floor San Francisco CA 94104 500000 3900000.00 111260247 09/25/2025 NASDAQ GM Common 07/24/2017 Pre-IPO investment Tango Therapeutics Inc N 500000 07/24/2017 Wire N Third Rock Ventu |
|
| September 17, 2025 |
144 0001688327 XXXXXXXX LIVE 0001819133 Tango Therapeutics, Inc. 001-39485 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215 (857) 320-4900 Third Rock Ventures IV, L.P. 10% Stockholder Common BTIG, LLC 350 Bush Street 9th Floor San Francisco CA 94104 363541 2672026.35 111260247 09/16/2025 NASDAQ GM Common 03/23/2017 Pre-IPO investment Tango Therapeutics Inc N 23067 03/23/2017 Wire Common 07/24/2017 P |
|
| September 8, 2025 |
144 0001688327 XXXXXXXX LIVE 0001819133 Tango Therapeutics, Inc. 001-39485 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215 (857) 320-4900 Third Rock Ventures IV, L.P. 10% Stockholder Common BTIG, LLC 350 Bush Street 9th Floor San Francisco CA 94104 86459 608628.13 111260247 09/08/2025 NASDAQ GM Common 03/23/2017 Pre-IPO investment Tango Therapeutics Inc N 86459 03/23/2017 Wire N Third Rock Ventures |
|
| September 5, 2025 |
144 0001688327 XXXXXXXX LIVE 0001819133 TANGO THERAPEUTICS, INC. 001-39485 201 Brookline Ave., Suite 901 Boston MA 02215 (857) 320-4900 Third Rock Ventures IV, L.P. 10% Stockholder Common BTIG, LLC 350 Bush Street 9th Floor San Francisco CA 94104 642906 4461767.00 111260247 09/05/2025 NASDAQ GM common 03/23/2017 Pre-IPO investment Tango Therapeutics Inc N 642906 03/23/2017 Wire N Third Rock Ventur |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 21, 2025 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 47-2452488 (State or other jurisdiction of incorporation) (Commissio |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q i113.ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39485 T |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): August 5, 2025 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission |
|
| August 5, 2025 |
Non-Employee Director Compensation Policy Tango Therapeutics, Inc. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Tango Therapeutics, Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its |
|
| August 5, 2025 |
Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights – First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors – – First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5 inhibitor in development for glioblastoma – BOSTON, August 5, 2025 (GLOBE NEWSWIRE) - Tango Therapeutics, Inc. |
|
| August 5, 2025 |
Confidential CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. |
|
| June 6, 2025 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TANGO THERAPEUTICS, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Tango Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The Corporation was origin |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 5, 2025 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 47-2452488 (State or other jurisdiction of incorporation) (Commission F |
|
| May 20, 2025 |
May 20, 2025 Barbara Weber, M.D. President and Chief Executive Officer Tango Therapeutics, Inc. 201 Brookline Avenue, Suite 901 Boston, MA 02215 Re: Tango Therapeutics, Inc. Registration Statement on Form S-3 Filed May 12, 2025 File No. 333-287202 Dear Barbara Weber M.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and |
|
| May 19, 2025 |
CORRESP VIA EDGAR May 19, 2025 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| May 12, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): May 12, 2025 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 12, 2025 |
As filed with the Securities and Exchange Commission on May 12, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on May 12, 2025 Registration No. |
|
| May 12, 2025 |
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights – Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 – – Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 – – Cash position of $217 million as of March 31, 2025; cash runway extended into 1Q 2027 - with reduction of preclinical spend – BOSTON, May 12, 2025 (GLOBE NEWSWIRE) - Tango Therapeutics, Inc. |
|
| May 12, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Tango Therapeutics, Inc. |
|
| May 12, 2025 |
Form of Senior Indenture between Registrant and one or more trustees to be named EX-4.5 Exhibit 4.5 TANGO THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’ |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q i113.ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39485 |
|
| May 12, 2025 |
Form of Subordinated Indenture between Registrant and one or more trustees to be named EX-4.6 Exhibit 4.6 TANGO THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Subordinated Debt Securities TABLE OF CONTENTS(1) Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trust |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| April 22, 2025 |
Tango Therapeutics, Inc. 2024 Annual Report to StockholdersUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERI |
|
| April 22, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| February 27, 2025 |
Insider Trading Policy of Tango Therapeutics, Inc. TANGO THERAPEUTICS, INC. Insider Trading POLICY This Insider Trading Policy (the “Insider Trading Policy”) is designed to prevent insider trading or the appearance of impropriety, to satisfy the obligations of Tango Therapeutics, Inc. and its subsidiaries (collectively, the “Company”) to reasonably supervise the activities of Company personnel, and to help Company personnel avoid the severe conseq |
|
| February 27, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Tango Therapeutics, Inc. |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39485 TANGO THERAPEUT |
|
| February 27, 2025 |
As filed with the Securities and Exchange Commission on February 27, 2025 As filed with the Securities and Exchange Commission on February 27, 2025 Registration No. |
|
| February 27, 2025 |
Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights – TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer – – Investigational New Drug (IND) application for TNG456, a next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor, cleared by FDA. |
|
| February 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): February 27, 2025 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commissi |
|
| February 14, 2025 |
AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection wi |
|
| January 13, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2025 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commissi |
|
| January 13, 2025 |
Exhibit 99.1 The next wave of targeted therapies in oncology Corporate Overview January 2025 | 1 Disclaimer and Safe Harbor Statement Certain statements in this presentation may be considered forward-looking statements. Forward-looking statements generally relate to future events, Tango’s future financial and operating performance, goals, expectations, beliefs, development plans, as well as develo |
|
| December 6, 2024 |
Exhibit 99 Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. |
|
| November 20, 2024 |
EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that each is responsible for the |
|
| November 20, 2024 |
TNGX / Tango Therapeutics, Inc. / TCG Crossover GP II, LLC - SC 13G Passive Investment SC 13G 1 d898449dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Tango Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 87583X109 (CUSIP Number) November 13, 2024 (Date of Event Which Requires Filing of This Statement) Check th |
|
| November 7, 2024 |
TNGX / Tango Therapeutics, Inc. / Boxer Capital Management, LLC Activist Investment SC 13D/A 1 ff409551813da-boxertango.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 6)* Tango Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 87583X1 |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 113.ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-394 |
|
| November 6, 2024 |
Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program – TNG462 demonstrated durable clinical activity across multiple tumor types, including non-small cell lung cancer (NSCLC) and pancreatic cancer, in ongoing phase 1/2 clinical trial, moving into full development – – Multiple TNG462 combination studies planned in 1H 2025 – – Clinical collaborati |
|
| November 6, 2024 |
Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights – Positive TNG462 clinical activity across multiple tumor types in the phase 1/2 clinical trial, program moving into full development with multiple combination studies – – Clinical collaboration established with Revolution Medicines to evaluate TNG462 in combination with RAS(ON) multi- and G12D-selective inhibitors – – Next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor, TNG456, planned to enter the clinic in 1H 2025 – – Strong cash position of $293 million as of September 30, 2024, with cash runway into 3Q 2026 to prioritize resourcing of TNG462 and TNG456 clinical trials – BOSTON, Mass. |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): November 6, 2024 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commissio |
|
| October 28, 2024 |
TNGX / Tango Therapeutics, Inc. / Boxer Capital Management, LLC Activist Investment SC 13D/A 1 ff404326213da5-boxertango.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 5)* Tango Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 87583X |
|
| October 15, 2024 |
TNGX / Tango Therapeutics, Inc. / Boxer Asset Management Inc. Activist Investment SC 13D/A 1 ff399376813da4-tango.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 4)* Tango Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 87583X109 ( |
|
| October 15, 2024 |
TNGX / Tango Therapeutics, Inc. / Boxer Capital, LLC Activist Investment SC 13D/A 1 ff399644213da4-tangoboxcap.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 4)* Tango Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 87583 |
|
| September 4, 2024 |
TNGX / Tango Therapeutics, Inc. / Third Rock Ventures IV, L.P. - SC 13D/A Activist Investment SC 13D/A 1 d857596dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Tango Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Class of Securities) 87583X109 (CUSIP Number) Kevin Gillis Third Rock Ventures, LLC 201 Brookline Ave, Suite 1401, Boston, MA 02215 (617) 585-2000 (Name, A |
|
| August 7, 2024 |
Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights – Dose expansion ongoing in TNG908 and TNG462 phase 1/2 clinical trials; comprehensive clinical data update for the PRMT5 program expected in 2H 2024 – – Patient enrollment is ongoing in TNG260 phase 1/2 clinical trial – – Strong cash position of $322 million as of June 30, 2024; cash runway into 2027 expected to fund clinical programs through proof-of-concept – BOSTON, Mass. |
|
| August 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2024 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission |
|
| August 7, 2024 |
Second Amended and Restated Certificate of Incorporation of Tango Therapeutics, Inc., as amended SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BCTG ACQUISITION CORP. |
|
| August 7, 2024 |
Non-Employee Director Compensation Policy. TANGO therapeutics, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Tango Therapeutics, Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 113.ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39485 TA |
|
| June 6, 2024 |
Certificate of Amendment of the Restated Certificate of Incorporation of Tango Therapeutics, Inc. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TANGO THERAPEUTICS, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Tango Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The Corporation was originally in |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 5, 2024 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission F |
|
| May 23, 2024 |
EX-99.1 2 d823505dex991.htm EX-99.1 Exhibit 99.1 Tango Therapeutics Announces Discontinuation of TNG348 Program – The phase 1/2 clinical trial of TNG348, a USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts – – Cash runway extended into 2027, PRMT5 and CoREST clinical programs remain on track – BOSTON, Mass. – May 23, 2024 – Tango Therapeutics, Inc. (NASDAQ: |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 23, 2024 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 47-2452488 (State or other jurisdiction of incorporation) (Commission F |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 113.ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39485 T |
|
| May 8, 2024 |
Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights – Dose expansion initiated in TNG908 phase 1/2 clinical trial – – Dose expansion expected to initiate in TNG462 phase 1/2 clinical trial in 2Q 2024 – – Clinical data expected in 2H 2024 from PRMT5 program – – Dose escalation ongoing in TNG260 and TNG348 clinical-stage precision oncology programs – – Strong cash position of $344 million as of March 31, 2024; cash runway into late 2026 expected to fund all clinical programs through proof-of-concept – BOSTON, Mass. |
|
| May 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2024 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 8, 2024 |
TNGX / Tango Therapeutics, Inc. / Southpoint Capital Advisors LP - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Tango Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 87583X109 (CUSIP Number) April 8, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| March 18, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Tango Therapeutics, Inc. |
|
| March 18, 2024 |
List of subsidiaries of Tango Therapeutics, Inc. Exhibit 21.1 Exhibit 21.1 List of Subsidiaries Tango Therapeutics Sub, Inc., a Delaware corporation Tango Securities Corporation, a Massachusetts corporation |
|
| March 18, 2024 |
As filed with the Securities and Exchange Commission on March 18, 2024 As filed with the Securities and Exchange Commission on March 18, 2024 Registration No. |
|
| March 18, 2024 |
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights – Dose escalation ongoing in four clinical-stage precision oncology programs; TNG908 phase 1/2 clinical data expected in 2024 – – First patient dosed in phase 1/2 clinical trial of TNG348 in patients with BRCA1/2-mutant and other HRD+ cancers – – FDA Orphan Drug Designation granted for TNG462 for the treatment of soft tissue sarcomas – – Strong cash position of $337 million as of December 31, 2023, combined with $42 million in proceeds from ATM in January 2024; cash runway into late 2026 expected to fund all clinical programs through proof-of-concept – BOSTON, Mass. |
|
| March 18, 2024 |
Tango Therapeutics, Inc. Compensation Recovery Policy TANGO THERAPEUTICS, INC. COMPENSATION RECOVERY POLICY Adopted as of September 14, 2023 Tango Therapeutics, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defin |
|
| March 18, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): March 18, 2024 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39485 TANGO THERAPEUT |
|
| February 14, 2024 |
TNGX / Tango Therapeutics, Inc. / Southpoint Capital Advisors LP - SC 13G/A Passive Investment SC 13G/A 1 d772348dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Tango Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 87583X109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the |
|
| February 13, 2024 |
TNGX / Tango Therapeutics, Inc. / GILEAD SCIENCES INC - SC 13G/A Passive Investment SC 13G/A 1 d756953dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* TANGO THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 87583X109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| February 9, 2024 |
TNGX / Tango Therapeutics, Inc. / FMR LLC Passive Investment SCHEDULE 13G Amendment No.3 TANGO THERAPEUTICS INC COMMON STOCK Cusip #87583X109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #87583X109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 9,786,656 Item 6: 0 Item 7: 9,787,350 Item 8: 0 Item 9: 9,787,350 Item 11: |
|
| February 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 7, 2024 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 47-2452488 (State or other jurisdiction of incorporation) (Commissi |
|
| November 8, 2023 |
Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights – Dose escalation ongoing in phase 1/2 trials of lead PRMT5 inhibitors TNG908 and TNG462; additional TNG908 clinical data expected 2024 – – Dose escalation ongoing in phase 1/2 trial of CoREST inhibitor TNG260 and pembrolizumab in patients with STK11 mutant solid tumors – – FDA Fast Track designation granted for TNG348, a novel USP1 inhibitor, for the treatment of BRCA1/2-mutant breast and ovarian cancer; phase 1/2 clinical trial initiation expected 1H 2024 – – Kanishka Pothula, partner at Nextech Ventures, appointed to Board of Directors, replacing Reid Huber, Ph. |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39485 TANGO THERAPEUTICS, INC. |
|
| November 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2023 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commissio |
|
| October 18, 2023 |
TNGX / Tango Therapeutics Inc / BCTG Holdings, LLC Activist Investment SC 13D/A 1 ff260961713da3-tango.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 3)* Tango Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 87583X109 (CUSIP Number) Josh La Grange Fried, Frank, Harris, Shriver & Jacobson LLP 801 17th Street, NW, |
|
| October 16, 2023 |
TNGX / Tango Therapeutics Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Tango Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87583X109 (CUSIP Number) October 13, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| September 21, 2023 |
TNGX / Tango Therapeutics Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Tango Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87583X109 (CUSIP Number) September 11, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| September 11, 2023 |
TNGX / Tango Therapeutics Inc / FMR LLC Passive Investment SCHEDULE 13G Amendment No.2 TANGO THERAPEUTICS INC COMMON STOCK Cusip #87583X109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #87583X109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 13,546,890 Item 6: 0 Item 7: 13,548,072 Item 8: 0 Item 9: 13,548,072 Item |
|
| September 7, 2023 |
United States securities and exchange commission logo September 7, 2023 Barbara Weber, M. |
|
| September 7, 2023 |
VIA EDGAR September 7, 2023 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| September 1, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Tango Therapeutics, Inc. |
|
| September 1, 2023 |
As filed with the Securities and Exchange Commission on September 1, 2023 Form S-3 Table of Contents As filed with the Securities and Exchange Commission on September 1, 2023 Registration No. |
|
| August 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): August 28, 2023 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission |
|
| August 21, 2023 |
TNGX / Tango Therapeutics Inc / Nextech Crossover I GP S.a r.l. - SC 13G Passive Investment SC 13G 1 tm2324134d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Tango Therapeutics, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 87583X109 (CUSIP Number) August 11, 2023 (Date of Event Which Requires Filing of this Statement) Check t |
|
| August 16, 2023 |
TNGX / Tango Therapeutics Inc / BCTG Holdings, LLC Activist Investment SC 13D/A 1 ff239281213da2-tango.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 2)* Tango Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 87583X109 (CUSIP Number) Josh La Grange Fried, Frank, Harris, Shriver & Jacobson LLP 801 17th Street, NW, |
|
| August 10, 2023 |
EX-10.1 Exhibit 10.1 Execution Version TANGO THERAPEUTICS, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (the “Agreement”) is made as of August 10, 2023 (the “Effective Date”), by and among Tango Therapeutics, Inc., a Delaware corporation (the “Company”), and the purchasers whose names and addresses are set forth on the signature pages hereof (each, a “Purchaser” and, colle |
|
| August 10, 2023 |
Tango Therapeutics Announces $80 million Private Placement Financing EX-99.1 Exhibit 99.1 Tango Therapeutics Announces $80 million Private Placement Financing BOSTON, Mass. – August 10, 2023 – Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, has agreed to sell approximately 15.5 million shares of its common stock (“Common Stock”) (or pre-funded |
|
| August 10, 2023 |
EX-4.1 Exhibit 4.1 THESE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE BUT HAVE BEEN OR WILL BE ISSUED IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED UNLES |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2023 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commissio |
|
| August 7, 2023 |
TANGO therapeutics, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Tango Therapeutics, Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its |
|
| August 7, 2023 |
Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights – First patient dosed in phase 1/2 trial of TNG462, a next-generation PRMT5 inhibitor for the treatment of MTAP-deleted tumors – – Dose escalation ongoing in phase 1/2 trial of TNG908, a novel brain-penetrant PRMT5 inhibitor for the treatment of MTAP-deleted tumors – – First patient dosed in phase 1/2 trial of TNG260, a first-in-class CoREST complex inhibitor, with pembrolizumab for the treatment STK11-mutant cancers – – Alan Huang, Ph. |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): August 3, 2023 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39485 TANGO THERAPEUTICS, INC. |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 6, 2023 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission F |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2023 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39485 TANGO THERAPEUTICS, INC. |
|
| May 9, 2023 |
Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights – Dose escalation update from ongoing TNG908 clinical trial confirms proof-of-mechanism for MTA-cooperative tumor-selective PRMT5 inhibition in MTAP-deleted cancers – – FDA clears IND application for TNG260, a first-in-class CoREST complex inhibitor for the treatment of STK11-mutant cancers – – Fast Track designation granted by FDA for TNG260 + anti-PD-1 antibody for the treatment of patients with advanced NSCLC with STK11-loss of function mutations – – Strong cash position of $334 million expected to support advancing precision oncology pipeline into 2026 – BOSTON, Mass. |
|
| April 24, 2023 |
Tango Therapeu�cs, Inc. 2022 Annual Report to Stockholders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHaANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PER |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 27, 2023 |
Exhibit 4.2 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary of certain provisions of Tango Therapeutics, Inc.’s (“Tango”, “we”, “our”) securities does not purport to be complete and is subject to the Second Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation” or “Charter”), the Am |
|
| March 27, 2023 |
List of subsidiaries of Tango Therapeutics, Inc. Exhibit 21.1 Exhibit 21.1 List of Subsidiaries Tango Therapeutics Sub, Inc., a Delaware corporation Tango Securities Corporation, a Massachusetts corporation |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): March 27, 2023 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHaANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39485 TANGO THERAPEU |
|
| March 27, 2023 |
Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights – Fast Track Designation granted to TNG462, next-generation MTA-Cooperative PRMT5 inhibitor – – Adam Crystal, M. |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 27, 2023 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 47-2452488 (State or other jurisdiction of incorporation) (Commiss |
|
| February 28, 2023 |
EX-99.1 Exhibit 99.1 Tango Therapeutics Announces Appointment of Adam Crystal, M.D., Ph.D. as President of Research and Development BOSTON, Mass. – February 28, 2023 – Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Adam Crystal, M.D., Ph.D. |
|
| February 14, 2023 |
TNGX / Tango Therapeutics, Inc. / Casdin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
TNGX / Tango Therapeutics, Inc. / Cormorant Asset Management, LP Passive Investment SC 13G/A 1 schedule13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Tango Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 87583X109 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 9, 2023 |
TNGX / Tango Therapeutics, Inc. / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.1 TANGO THERAPEUTICS INC COMMON STOCK Cusip #87583X109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #87583X109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 9,083,074 Item 6: 0 Item 7: 9,083,679 Item 8: 0 Item |
|
| February 7, 2023 |
As filed with the Securities and Exchange Commission on February 7, 2023 S-8 As filed with the Securities and Exchange Commission on February 7, 2023 Registration No. |
|
| February 7, 2023 |
EX-99.1 Exhibit 99.1 TANGO THERAPEUTICS, INC. 2023 INDUCEMENT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Tango Therapeutics, Inc. 2023 Inducement Plan (as amended from time to time, the “Plan”). The purpose of the Plan is to enable Tango Therapeutics, Inc. (the “Company”) to grant equity awards to induce highly-qualified prospective officers and employees |
|
| February 7, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Tango Therapeutics, Inc. |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): November 10, 2022 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commissi |
|
| November 10, 2022 |
Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights ? Clinical Trial Application (CTA) for TNG908, an MTA-cooperative PRMT5 inhibitor, approved by the National Agency for the Safety of Medicines (ANSM) in France ? ? TNG260 disclosed as a first-in-class CoREST complex inhibitor for treatment of STK11-mutant cancers ? ? TNG348 declared as a USP1 inhibitor development candidate for treatment of BRCA1/2 mutant cancers ? ? Aaron Weitzman, M. |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q usROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39485 TANGO THERAPEUTICS, INC. |
|
| September 21, 2022 |
As filed with the Securities and Exchange Commission on September 21, 2022 Table of Contents As filed with the Securities and Exchange Commission on September 21, 2022 Registration Statement No. |
|
| September 8, 2022 |
VIA EDGAR September 8, 2022 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| September 7, 2022 |
United States securities and exchange commission logo September 7, 2022 Barbara Weber President and Chief Executive Officer Tango Therapeutics, Inc. |
|
| September 1, 2022 |
Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM September 1, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Tango Therapeutics, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s comm |
|
| September 1, 2022 |
As filed with the Securities and Exchange Commission on September 1, 2022 Table of Contents As filed with the Securities and Exchange Commission on September 1, 2022 Registration No. |
|
| September 1, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) Tango Therapeutics, Inc. |
|
| September 1, 2022 |
Form of Senior Indenture between Registrant and one or more trustees to be named Exhibit 4.5 TANGO THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities. 4 Section 2.02 Form of Securities and Trustee?s Cer |
|
| September 1, 2022 |
Form of Subordinated Indenture between Registrant and one or more trustees to be named Exhibit 4.6 TANGO THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Subordinated Debt Securities TABLE OF CONTENTS(1) Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Ce |
|
| August 10, 2022 |
Up to 68,175,412 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-259448 Prospectus Supplement No. 3 (to Prospectus dated March 28, 2022) Up to 68,175,412 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated March 28, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-259448). This prospectus supplem |
|
| August 10, 2022 |
Tango Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights ? Patients with MTAP-deleted solid tumors being actively enrolled in ongoing Phase 1/2 trial of TNG908, an MTA-cooperative PRMT5 inhibitor ? ? Received Orphan Drug Designation in US for the treatment of malignant peripheral nerve sheath tumors with TNG908 ? CAMBRIDGE, Mass. |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q usROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39485 TANGO THERAPEUTICS, INC. |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2022 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission |
|
| July 11, 2022 |
TNGX / Tango Therapeutics, Inc. / Southpoint Capital Advisors LP - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Tango Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 87583X109 (CUSIP Number) June 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| June 10, 2022 |
Up to 68,175,412 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-259448 Prospectus Supplement No. 2 (to Prospectus dated March 28, 2022) Up to 68,175,412 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated March 28, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (333-259448). This prospectus supplement is being filed to update |
|
| June 10, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGECOMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): June 8, 2022 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 11, 2022 |
Tango Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights – Phase 1/2 trial of TNG908, a synthetic lethal PRMT5 inhibitor, for the treatment of MTAP-deleted solid tumors open for enrollment – – Declared TNG462 as a development candidate - a next-generation PRMT5 inhibitor for MTAP-deleted solid tumors – – Declared TNG260 as a development candidate - an inhibitor of an undisclosed synthetic lethal target that reverses the immune evasion effect of STK11 loss-of-function mutations – – Strong cash position of $450 million expected to support advancing discovery and clinical pipeline into second half of 2024 – CAMBRIDGE, Mass. |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39485 TANGO THERAPEUTICS, INC. |
|
| May 11, 2022 |
Up to 68,175,412 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-259448 Prospectus Supplement No. 1 (to Prospectus dated March 28, 2022) Up to 68,175,412 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated March 28, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-259448). This prospectus supplem |
|
| May 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGECOMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 Date of Report (Date of earliest event reported): May 11, 2022 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 11, 2022 |
Non-Employee Director Compensation Policy TANGO therapeutics, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the ?Policy?) of Tango Therapeutics, Inc. (the ?Company?) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries (?Outsi |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 28, 2022 |
Exhibit 4.2 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary of certain provisions of Tango Therapeutics, Inc.?s (?Tango?, ?we?, ?our?) securities does not purport to be complete and is subject to the Second Amended and Restated Certificate of Incorporation (the ?Certificate of Incorporation? or ?Charter?), the Am |
|
| March 28, 2022 |
Exhibit 99.1 Tango Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights - TNG908 receives Fast Track designation, expects Phase 1/2 trial to start in 2Q 2022 - Pipeline programs progressing throughout 2022 - - Strong cash position of $485 million expected to support operations into second half of 2024 - CAMBRIDGE, Mass. ? March 28, 2022 ? Tango |
|
| March 28, 2022 |
As filed with the Securities and Exchange Commission on March 28, 2022 As filed with the Securities and Exchange Commission on March 28, 2022 Registration No. |
|
| March 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 28, 2022 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission |
|
| March 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39485 TANGO THERAPEUT |
|
| March 28, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on March 28, 2022 Registration Statement No. |
|
| March 28, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Tango Therapeutics, Inc. |
|
| March 28, 2022 |
Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. |
|
| February 14, 2022 |
TNGX / Tango Therapeutics, Inc. / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Tango Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 87583X109 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 14, 2022 |
TNGX / Tango Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Tango Therapeutics, Inc. (f/k/a BCTG Acquisition Corp.) (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87583X109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check th |
|
| February 14, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 14, 2022, is by and between Cormorant Asset Management, LP and Bihua Chen (collectively, the ?Filers?). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and/or 13G with respect to shares of Common Stock of Tango Therapeutics, Inc. ben |
|
| February 10, 2022 |
TNGX / Tango Therapeutics, Inc. / Southpoint Capital Advisors LP - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Tango Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 87583X109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 9, 2022 |
TNGX / Tango Therapeutics, Inc. / FMR LLC Passive Investment SCHEDULE 13G Amendment No. 0 TANGO THERAPEUTICS INC COMMON STOCK Cusip #87583X109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #87583X109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,073,001 Item 6: 0 Item 7: 7,182,188 Item 8: 0 Item 9: 7,182,188 Item 11 |
|
| January 4, 2022 |
TNGX / Tango Therapeutics, Inc. / BCTG Holdings, LLC - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 4, 2022 |
EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D and any amendments to it with respect to Common Stock, $0. |
|
| November 9, 2021 |
Exhibit 99.1 Tango Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights ? Strong cash position of $504 million supports advancing discovery and clinical pipeline into second half of 2024 ? ? On track for IND filing in fourth quarter of 2021 for TNG908, an MTA-cooperative PRMT5 inhibitor that is synthetic lethal with MTAP deletion, for multiple cancers ? CAMBRI |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39485 TANGO THERAPEUTICS, INC. |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 9, 2021 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 47-2452488 (State or other jurisdiction of incorporation) (Commissi |
|
| November 9, 2021 |
Up to 68,034,602 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-259448 Prospectus Supplement No. 1 (to Prospectus dated October 7, 2021) Up to 68,034,602 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated October 7, 2021 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (333-259448). This prospectus supplement is being filed to updat |
|
| October 14, 2021 |
As filed with the Securities and Exchange Commission on October 14, 2021 Registration No. |
|
| October 14, 2021 |
Exhibit 4.2 AMENDED AND RESTATED BY-LAWS OF BCTG ACQUISITION CORP. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place may |
|
| October 14, 2021 |
Exhibit 99.4 TANGO THERAPEUTICS, INC. 2017 STOCK OPTION AND GRANT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Tango Therapeutics, Inc. 2017 Stock Option and Grant Plan (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, directors, Consultants and other key persons of Tango Therapeutics, Inc., a Delaware corporation (inc |
|
| October 8, 2021 |
Up to 68,034,602 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-259448 PROSPECTUS Up to 68,034,602 Shares of Common Stock This prospectus relates to the offer and sale, from time to time, by the selling securityholders named in this prospectus, or the Selling Securityholders, or any of their pledgees, donees, assignees and successors-in-interest, or collectively, the permitted transferees, |
|
| September 29, 2021 |
Up to 68,175,412 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-259448 PROSPECTUS Up to 68,175,412 Shares of Common Stock This prospectus relates to the offer and sale, from time to time, by the selling securityholders named in this prospectus, or the Selling Securityholders, or any of their pledgees, donees, assignees and successors-in-interest, or collectively, the permitted transferees, |
|
| September 27, 2021 |
TANGO THERAPEUTICS, INC. 100 Binney St, Suite 700 Cambridge, MA 02142 TANGO THERAPEUTICS, INC. 100 Binney St, Suite 700 Cambridge, MA 02142 VIA EDGAR September 27, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Tim Buchmiller Re: Tango Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-1 Filed September 10, 2021 File No. 333-259448 Dear Mr. Buchmiller: |
|
| September 17, 2021 |
United States securities and exchange commission logo September 17, 2021 Barbara Weber, M. |
|
| September 10, 2021 |
Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BCTG ACQUISITION CORP. August 10, 2021 BCTG Acquisition Corp., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), DOES HEREBY CERTIFY AS FOLLOWS: 1. The name of the Corporation is ?BCTG Acquisition Corp.? The original certificate of incorporation was filed with the Secretary of St |
|
| September 10, 2021 |
TNGX / Tango Therapeutics, Inc. / GILEAD SCIENCES INC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TANGO THERAPEUTICS, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 87583X109 (CUSIP Number) August 10, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| September 10, 2021 |
List of subsidiaries of Tango Therapeutics, Inc. Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation Tango Therapeutics Sub, Inc. Delaware Tango Securities Corporation Massachusetts |
|
| September 10, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on September 10 , 2021 Registration Statement No. |
|
| August 20, 2021 |
TNGX / Tango Therapeutics, Inc. / BCTG Holdings, LLC - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 20, 2021 |
EX-99.1 2 d160102dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D and any amendments to it with respect to Common Stock, $0.001 par value per share, of Tango Therapeutics Inc. and further agree that |
|
| August 19, 2021 |
TNGX / Tango Therapeutics, Inc. / Third Rock Ventures IV, L.P. - SC 13D Activist Investment SC 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Tango Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Class of Securities) 87583X109 (CUSIP Number) Kevin Gillis Third Rock Ventures, LLC 29 Newbury Street, 3rd Floor, Boston, MA 02116 (617) 585-2000 (Name, Address and Telephone Number of Per |
|
| August 19, 2021 |
Exhibit 99.1 CUSIP: 87583X109 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge t |
|
| August 19, 2021 |
TNGX / Tango Therapeutics, Inc. / Casdin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 13, 2021 |
Exhibit 10.11 TANGO THERAPEUTICS, INC. SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN 1. Purpose This Senior Executive Cash Incentive Bonus Plan (the ?Incentive Plan?) is intended to provide an incentive for superior work and to motivate eligible executives of Tango Therapeutics, Inc. (the ?Company?) and its subsidiaries toward even higher achievement and business results, to tie their goals and inter |
|
| August 13, 2021 |
Exhibit 16.1 August 13, 2021 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Ladies and Gentlemen: We have read the statements of Tango Therapeutics, Inc. (formerly known as BCTG Acquisition Corp.) under Item 4.01(a) of its Form 8-K dated August 13, 2021. We agree with the statements concerning our Firm under Item 4.01(a), in which we were |
|
| August 13, 2021 |
Exhibit 10.7 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made between Tango Therapeutics, Inc., a Delaware corporation (the ?Company?), and (the ?Executive?) and is effective as of the closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 13, 2021, by and among BCTG Acquisition Corp., BCTG Merger Sub Inc. and the Company (the ?Effective |
|
| August 13, 2021 |
Exhibit 10.4 TANGO THERAPEUTICS, INC. 2021 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Tango Therapeutics, Inc. 2021 Stock Option and Incentive Plan (as amended from time to time, the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Tango Therapeutics, I |
|
| August 13, 2021 |
Exhibit 99.3 BCTG ACQUISITION CORP. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2021 December 31, 2020 Assets: (Unaudited) Current assets: Cash $ 582,938 $ 1,314,085 Prepaid expenses 151,355 183,496 Total current assets 734,293 1,497,581 Investments held in Trust Account 166,815,023 166,815,235 Total Assets $ 167,549,316 $ 168,312,816 Liabilities and Stockholders? Equity: Current liabilities: A |
|
| August 13, 2021 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.4 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Capitalized terms used but not defined in this Exhibit 99.2 shall have the meanings ascribed to them in the Current Report on Form 8-K (the ?Form 8-K?) filed with the Securities and Exchange Commission (the ?SEC?) on August 13, 2021 and, if not defined in the Form 8-K, included in the Company?s effective proxy statement/pros |
|
| August 13, 2021 |
Exhibit 99.2 TANGO THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share amounts) (Unaudited) June 30, 2021 December 31, 2020 Assets Current assets: Cash and cash equivalents $ 50,902 $ 28,381 Marketable securities 147,452 161,939 Accounts receivable 2,000 2,000 Prepaid expenses and other current assets 1,707 1,312 Total current assets 202,061 193,632 Property and eq |
|
| August 13, 2021 |
Exhibit 10.9 TANGO THERAPEUTICS, INC. FORM OF DIRECTOR INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of by and between Tango Therapeutics, Inc., a Delaware corporation (the ?Company?), and (?Indemnitee?). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company; WHEREAS, in |
|
| August 13, 2021 |
Exhibit 10.2 AMENDED AND RESTATED REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT (this ?Agreement?) is entered into as of the 10th day of August, 2021, is made and entered into by and among. TANGO THERAPEUTICS, INC. a Delaware corporation (the ?Company?), and certain former stockholders of Tango Therapeutics, Inc. (?Old Tango?) |
|
| August 13, 2021 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF TANGO Exhibit 99.1 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF TANGO Management?s discussion and analysis of our financial condition and results of operations should be read together with Tango?s unaudited condensed consolidated financial statements and related notes appearing elsewhere in this Form 8-K and with Tango?s audited consolidated financial statemen |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2021 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commissio |
|
| August 13, 2021 |
Exhibit 10.10 TANGO THERAPEUTICS, INC. FORM OF OFFICER INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of by and between Tango Therapeutics, Inc., a Delaware corporation (the ?Company?), and (?Indemnitee?). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company; WHEREAS, in |
|
| August 13, 2021 |
Exhibit 10.8 TANGO THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the ?Policy?) of Tango Therapeutics, Inc. (the ?Company?) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidi |
|
| August 13, 2021 |
Exhibit 10.6 TANGO THERAPEUTICS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Tango Therapeutics, Inc. 2021 Employee Stock Purchase Plan (the ?Plan?) is to provide eligible employees of Tango Therapeutics, Inc. (the ?Company?) and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase shares of the Company?s common stock, par value $0.001 per share (the ? |
|
| August 13, 2021 |
Exhibit 10.5 INCENTIVE STOCK OPTION AGREEMENT UNDER THE TANGO THERAPEUTICS, INC. 2021 STOCK OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: $ [FMV on Grant Date (110% of FMV if a 10% owner)] Grant Date: Expiration Date: [No more than 10 years (5 years if a 10% owner)] Pursuant to the Tango Therapeutics, Inc. 2021 Stock Option and Incentive Plan, a |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to BCTG ACQUISITION CORP. (Exact name of registrant as spe |
|
| July 19, 2021 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-255354 PROXY STATEMENT FOR SPECIAL MEETING OF BCTG ACQUISITION CORP. AND PROSPECTUS FOR SHARES OF COMMON STOCK OF BCTG ACQUISITION CORP. BCTG Acquisition Corp. 12860 El Camino Real, Suite 300 San Diego, CA 92130 To the Stockholders of BCTG Acquisition Corp.: You are cordially invited to attend the Special Meeting of Stockholders (the ?Special M |
|
| July 16, 2021 |
Consent to Reference in Proxy Statement/Prospectus EX-99.7 10 ea144230ex99-7bctgacq.htm CONSENT OF LESLEY CALHOUN TO BE NAMED AS A DIRECTOR Exhibit 99.7 July 14, 2021 Consent to Reference in Proxy Statement/Prospectus BCTG Acquisition Corp, Inc. (the “Company”) is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”) |
|
| July 16, 2021 |
As filed with the U.S. Securities and Exchange Commission on July 15, 2021 As filed with the U.S. Securities and Exchange Commission on July 15, 2021 Registration No. 333-255354 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BCTG Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 6770 85-1195036 (State or Other Jurisdiction of Incorp |
|
| July 16, 2021 |
Consent to Reference in Proxy Statement/Prospectus EX-99.6 9 ea144230ex99-6bctgacq.htm CONSENT OF MALTE PETERS TO BE NAMED AS A DIRECTOR Exhibit 99.6 July 14, 2021 Consent to Reference in Proxy Statement/Prospectus BCTG Acquisition Corp, Inc. (the “Company”) is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). I |
|
| July 16, 2021 |
Consent to Reference in Proxy Statement/Prospectus EX-99.8 11 ea144230ex99-8bctgacq.htm CONSENT OF MACE ROTHENBERG TO BE NAMED AS A DIRECTOR Exhibit 99.8 July 14, 2021 Consent to Reference in Proxy Statement/Prospectus BCTG Acquisition Corp, Inc. (the “Company”) is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act” |
|
| July 16, 2021 |
EX-21.1 4 ea144230ex21-1bctgacq.htm LIST OF SUBSIDIARIES Exhibit 21.1 List of Subsidiaries BCTG Acquisition Corp. BCTG Merger Sub Inc., a Delaware corporation Tango Therapeutics, Inc. Tango Securities Corporation, a Massachusetts corporation |
|
| July 16, 2021 |
EX-4.5 2 ea144230ex4-5bctgacq.htm SPECIMEN COMMON STOCK CERTIFICATE OF THE COMBINED ENTITY Exhibit 4.5 NUMBER C- SHARES SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP TANGO THERAPEUTICS, INC. COMMON STOCK THIS CERTIFIES THAT is the owner of fully paid and non-assessable shares of common stock, par value $0.001 per share (the “Common Stock”), of Tango Therapeutics, Inc., a Delaware corporation (the “Com |
|
| July 16, 2021 |
Consent to Reference in Proxy Statement/Prospectus EX-99.2 5 ea144230ex99-2bctgacq.htm CONSENT OF BARBARA WEBER TO BE NAMED AS A DIRECTOR Exhibit 99.2 July 14, 2021 Consent to Reference in Proxy Statement/Prospectus BCTG Acquisition Corp, Inc. (the “Company”) is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). |
|
| July 16, 2021 |
Consent to Reference in Proxy Statement/Prospectus EX-99.5 8 ea144230ex99-5bctgacq.htm CONSENT OF REID HUBER TO BE NAMED AS A DIRECTOR Exhibit 99.5 July 14, 2021 Consent to Reference in Proxy Statement/Prospectus BCTG Acquisition Corp, Inc. (the “Company”) is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In |
|
| July 16, 2021 |
Consent to Reference in Proxy Statement/Prospectus EX-99.3 6 ea144230ex99-3bctgacq.htm CONSENT OF ALEXIS BORISY TO BE NAMED AS A DIRECTOR Exhibit 99.3 July 14, 2021 Consent to Reference in Proxy Statement/Prospectus BCTG Acquisition Corp, Inc. (the “Company”) is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). |
|
| July 16, 2021 |
July 16, 2021 Aaron I. Davis Chief Executive Officer BCTG Acquisition Corp. 12860 El Camino Real, Suite 300 San Diego, CA 92130 Re: BCTG Acquisition Corp. Form S-4, as amended Exhibit Nos. 10.19 and 10.20 Filed April 20, 2021 File No. 333-255354 Dear Mr. Davis: We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your suppleme |
|
| July 16, 2021 |
Consent to Reference in Proxy Statement/Prospectus EX-99.4 7 ea144230ex99-4bctgacq.htm CONSENT OF AARON DAVIS TO BE NAMED AS A DIRECTOR Exhibit 99.4 July 14, 2021 Consent to Reference in Proxy Statement/Prospectus BCTG Acquisition Corp, Inc. (the “Company”) is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In |
|
| July 15, 2021 |
BCTG Acquisition Corp. 12860 El Camino Real, Suite 300 San Diego, CA 92130 (858) 400-3120 BCTG Acquisition Corp. 12860 El Camino Real, Suite 300 San Diego, CA 92130 (858) 400-3120 July 15, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Irene Paik and Christine Westbrook Re: BCTG Acquisition Corp. Registration Statement on Form S-4 Filed April 20, 2021, as amended Registration No. 333-255354 Dea |
